How do you adjust transplant-benefit–based decision-making for HCC patients with prior immune checkpoint inhibitor exposure, given the potential for increased peri-transplant rejection or graft loss?

Some programs aim not to proceed with transplantation (LT) for 1 month subsequent to the administration of immunotherapy in order to avoid rejection. However, this is not often feasible, and the reality is that the half-life of these medications can be closer to 50-60 days. My personal opinion is that if there is heightened awareness of this risk and of these patients, these patients can be managed appropriately by giving more upfront immunosuppression (IS) and by not tapering IS as rapidly post...